Structural Heart Devices Market Set to Expand and Reach ~USD 25 Billion by 2032 Amid Rising Demand for Minimally Invasive Solutions | DelveInsight

The rising demand for structural heart devices is largely fueled by the increasing prevalence of structural heart conditions such as valve disorders, congenital defects, and related ailments. Additionally, a growing shift toward minimally invasive procedures, along with heightened product development and launch efforts by major industry players, is anticipated to significantly boost the structural heart devices market from 2025 to 2032.

New York, USA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Structural Heart Devices Market Set to Expand and Reach ~USD 25 Billion by 2032 Amid Rising Demand for Minimally Invasive Solutions | DelveInsight

The rising demand for structural heart devices is largely fueled by the increasing prevalence of structural heart conditions such as valve disorders, congenital defects, and related ailments. Additionally, a growing shift toward minimally invasive procedures, along with heightened product development and launch efforts by major industry players, is anticipated to significantly boost the structural heart devices market from 2025 to 2032.

DelveInsight’s Structural Heart Devices Market Insights report provides the current and forecast market analysis, individual leading structural heart devices companies’ market shares, challenges, structural heart devices market drivers, barriers, trends, and key structural heart devices companies such as Medtronic, Boston Scientific Corporation, Braile Biomedica, JOTEC GmbH, Edwards Life Sciences Corporation, Valcare Medical, W. L. Gore & Associates, Inc., Abbott, Cardiovascular Systems, Inc., and others in the market.

Structural Heart Devices Overview

Structural heart devices are specialized medical devices used to treat abnormalities in the heart's structure, such as defects in the heart valves, walls, or chambers. These devices include transcatheter heart valves, occluders, annuloplasty rings, and repair clips, among others. They are designed to improve blood flow, restore normal heart function, and reduce the risk of complications such as heart failure, stroke, or arrhythmias. Structural heart interventions have become increasingly less invasive with the advancement of transcatheter techniques, which offer patients quicker recovery times, reduced procedural risks, and better overall outcomes compared to traditional open-heart surgery.

Structural Heart Devices Regional Market Insights

North America is anticipated to command the largest share of the structural heart devices market in the coming years, fueled by multiple critical factors. This leadership position is primarily due to the growing incidence of structural heart diseases such as valvular disorders, congenital defects, and other cardiac anomalies. The region’s preference for minimally invasive interventions is also on the rise, supported by its advanced healthcare infrastructure and widespread integration of innovative medical technologies. Additionally, a supportive regulatory framework, characterized by frequent product approvals and the introduction of novel devices, continues to bolster market expansion.

Leading companies in the sector are actively advancing the therapeutic landscape through innovation. For example, in May 2025, Edwards Lifesciences received U.S. FDA approval for its SAPIEN 3 Transcatheter Aortic Valve Replacement (TAVR) system to treat asymptomatic patients with severe aortic stenosis. This was the first FDA clearance for TAVR in this patient group, significantly broadening the treatment base. These kinds of breakthroughs, along with the high prevalence of cardiac conditions and a well-established healthcare ecosystem, are key growth drivers in the region.

As a result, the convergence of increasing structural heart disease cases and continuous technological advancement is expected to strongly drive the North American structural heart devices market from 2025 through 2032.

To know more about why North America is leading the market growth in the structural heart devices market, get a snapshot of the Structural Heart Devices Market Outlook

Recent Developments in the Structural Heart Devices Market

• In May 2025, Edwards Lifesciences announced that the U.S. FDA had approved the use of its SAPIEN 3 Transcatheter Aortic Valve Replacement (TAVR) platform for patients with severe aortic stenosis (AS) who are asymptomatic.
• In April 2025, Edwards Lifesciences announced that its SAPIEN M3 mitral valve replacement system received CE Mark approval. The device is approved for treating patients with moderate-to-severe or severe mitral regurgitation (MR) who are not suitable for surgery or transcatheter edge-to-edge repair (TEER). The SAPIEN M3 is the first transcatheter mitral valve replacement system approved for use through a transfemoral (through the leg) approach, offering a minimally invasive option for patients with limited treatment choices.
• In March 2025, Abbott announced new results from its TRILUMINATE™ Pivotal trial, showing that the TriClip™ TEER system provides significant and lasting improvement in tricuspid regurgitation (TR) after two years. The data also showed that TriClip reduced heart failure-related hospitalizations and improved long-term quality of life compared to standard medical therapy.

To read more about the latest highlights related to the structural heart devices market, get a snapshot of the key highlights entailed in the Structural Heart Devices

Key Players in the Structural Heart Devices Market

The structural heart devices market is highly competitive and features a mix of well-established medical technology giants and emerging players. Key companies driving innovation and market growth include Medtronic, Boston Scientific Corporation, Braile Biomedica, JOTEC GmbH, Edwards Life Sciences Corporation, Valcare Medical, W. L. Gore & Associates, Inc., Abbott, Cardiovascular Systems, Inc., XELTIS BV, JenaValve Technology, Inc., Biomerics, Lepu Medical Technology (Beijing) Co., Ltd, Livanova plc, Comed B.V., TORAY INDUSTRIES INC., Occlutech International AB, Microport Scientific Corporation, Meril Life Sciences, Venus Medtech (Hangzhou) Inc., and others. These firms have robust portfolios encompassing transcatheter heart valves, closure devices, and repair systems, supported by significant investments in R&D, regulatory approvals, and global distribution networks. In addition to these leading companies, several emerging players and niche innovators are contributing to the dynamic landscape.

Which MedTech key players in the structural heart devices market are set to emerge as the trendsetter explore @ Top Structural Heart Devices Companies

Structural Heart Devices Market Key Factor Analysis

Structural Heart Devices Market Drivers

The structural heart devices market is primarily driven by the growing prevalence of structural heart diseases, such as valvular and congenital heart defects, which has led to an increasing demand for effective treatment solutions. Additionally, there is a notable shift toward minimally invasive procedures, driven by their reduced recovery times, lower risk profiles, and improved patient outcomes. This evolving treatment landscape is further supported by the continuous product development and launch activities by key players, who are introducing advanced and innovative devices to meet the rising clinical needs and expand their market presence.

Structural Heart Devices Market Restraints and Challenges

One of the key restraints in the structural heart devices market is the frequent occurrence of product failures and recalls, which can significantly undermine patient and physician confidence in these technologies. These incidents not only pose safety risks but also lead to increased scrutiny from regulatory authorities. Coupled with this is the challenge of stringent regulatory requirements for product approvals, which can delay the introduction of innovative devices into the market. Together, these factors create a complex and high-risk environment for manufacturers, potentially limiting market growth and innovation.

Structural Heart Devices Market Opportunities

The structural heart devices market presents a significant opportunity driven by the integration of advanced technologies such as digital twins and artificial intelligence (AI). These innovations are transforming the design, testing, and optimization processes of structural heart devices, enabling personalized treatment planning, predictive maintenance, and improved clinical outcomes. Digital twin technology allows for the creation of highly accurate virtual models of patient-specific heart anatomies, enhancing pre-procedural planning and device fitment. Meanwhile, AI-powered analytics support real-time decision-making and risk stratification, further improving procedural success rates. This technological evolution is poised to accelerate product development cycles and expand the adoption of next-generation structural heart solutions across global markets.

Get a sneak peek at the structural heart devices market dynamics @ Global Structural Heart Devices Market Report

Structural Heart Devices Market Assessment

• Structural Heart Devices Market Segmentation
  • Structural Heart Devices Market Segmentation By Product Type: Repair Devices (Occluders, Annuloplasty Devices, Valvuloplasty Devices, and Others) and Replacement Devices (Mechanical Heart Valves and Tissue Heart Valves)
  • Structural Heart Devices Market Segmentation By Application: Atrial Septal Defect, Aortic Valve Stenosis, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Regurgitation, and Others
  • Structural Heart Devices Market Segmentation By End User: Hospitals, Ambulatory Surgical Centers, and Others
  • Structural Heart Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing the structural heart devices market by 2032? Click to get a snapshot of the Structural Heart Devices Market Analysis

Table of Contents 

Related Reports

Prosthetic Heart Valves Market

Prosthetic Heart Valves Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key prosthetic heart valves companies, including Medtronic plc., Abott., Edwards Lifesciences Corp., Corcym Srl, Boston Scientific Corporation, LivaNova PLC., Lepu Medical Technology Co., Ltd., CryoLife, Inc., Symetis SA, Jenavalve Technology, Inc., Braile Biomédica, Labcor Laboratorios Ltd., ShockWave Medical, Inc., Meril Life Sciences, TTK Healthcare Limited, among others.

Tissue Heart Valves Devices Market

Tissue Heart Valves Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key tissue heart valves devices companies, including Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), among others.

Congenital Heart Defect Devices Market

Congenital Heart Defect Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key congenital heart defect devices companies, including Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, W. L. Gore & Associates, Inc., Occlutech International AB, Cardia, Inc., and Lifetech Scientific Co., Ltd., Cepheid, Abingdon Health, among others.

Heart Closure Devices Market

Heart Closure Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key heart closure devices companies, including Abbott, W. L. Gore & Associates, Inc., Boston Scientific Corporation, Occlutech, Heartstitch, SMT, Cardia, Inc., Lifetech Scientific, Lepu Medical Technology(Beijing)Co., Ltd., ATRICURE, INC., among others.

Transcatheter Heart Valve Replacement Devices Market

Transcatheter Heart Valve Replacement Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key transcatheter heart valve replacement devices companies, including Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomédica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679

https://www.delveinsight.com/medical-devices

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.